Is There a Catalyst Out There For Checkpoint Therapeutics, Inc. (:CKPT)

As of late, the Street has taken a bit closer look at shares of Checkpoint Therapeutics, Inc. (:CKPT). In the latest session the stock moved -3.22%, putting the stock value at $2.86.

Here we’ll take a quick glance at how the stock price is currently trading in relation to some of its simple moving averages. At current levels, Checkpoint Therapeutics, Inc. (:CKPT) shares have been seen trading -4.64% away from the 20-day moving average. The stock has been recently separated from the 50-day moving average by -9.93%. Using a broader approach, shares have been trading -5.48% off of the 200-day moving average. After the latest check-in, company stock is -31.86% off of the 50 day high and 11.96% away from the 50 day low price.

With most types of investments, there is typically some level of risk. This is no different when dealing with the stock market. Investors have to decide how much risk is acceptable and plan accordingly. Many new stock market investors face the challenge of deciding where to begin. Following strategies that have proven to work in the past may be one way to go. Many investors will look to mimic the strategies of the most celebrated investors. Although this may be a good way to start, it may be necessary to fully understand every aspect that those successful investors examine. Blindly following trading plans without doing the proper research can lead to future trouble down the line if there is indeed a market shake-up.

In terms of performance, shares of Checkpoint Therapeutics, Inc. (:CKPT) are 56.87% since the start of 2016. Over the past week, shares are -7.31%. Moving out to look at the previous month performance, the stock is at -7.90%. For the quarter, performance is at -27.74%. During the past six months, Checkpoint Therapeutics, Inc. (:CKPT)’s stock has been -4.52% and -31.04% for the last 12 months.

One of the biggest downfalls of the individual investor is not being able to take losses when it becomes necessary. Of course nobody wants to take a loss, but the repercussions of not letting go of a losing stock can end up sealing the demise of the well-intentioned investor. Many professionals would probably agree that the pain of realizing a loss is more intense than the joy of picking a winner. Investors who become reluctant to sell losers may be delaying the inevitable and essentially suffocating the portfolio. Not addressing the losing side can have severe negative effects on the long-term health of the portfolio. Investors may have to find a way to face the music and sell when they realize that a trade has gone sour.

Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts. Examples of analysis performed within this article are only examples. 

Leave a Reply

Your email address will not be published. Required fields are marked *